



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

8 May 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021) (n, %)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
Eligible	6,345,070	1,113,003	452,826	291,661	315,367	178,459	169,768	99,711	26,772
New (1st dose)	38,982	11,230	2,449	1,894	1,929	1,837	757	958	149
New (2nd dose)	76,790	11,486	2,642	2,487	2,944	1,181	2,119	928	675
Total (1st dose)	3,662,587	586,943	229,755	156,387	180,874	115,938	104,185	61,565	18,328
Total (2nd dose)	473,994	71,214	23,591	18,117	29,192	14,651	11,910	12,670	4,442
% (1st dose)	57.7	52.7	50.7	53.6	57.4	65.0	61.4	61.7	68.5
% (2nd dose)	7.5	6.4	5.2	6.2	9.3	8.2	7.0	12.7	16.6
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
Eligible	1,347,936	253,663	222,095	309,999	300,976	337,024	413,587	430,228	81,995
New (1st dose)	6,315	1,095	931	1,119	1,230	2,989	1,804	1,467	829
New (2nd dose)	15,032	3,688	3,114	4,188	3,163	6,756	7,848	7,736	803
Total (1st dose)	800,759	147,540	135,568	178,630	186,062	218,426	234,763	261,260	45,604
Total (2nd dose)	81,836	26,041	24,854	23,952	25,710	31,021	29,726	34,985	10,082
% (1st dose)	59.4	58.2	61.0	57.6	61.8	64.8	56.8	60.7	55.6
% (2nd dose)	6.1	10.3	11.2	7.7	8.5	9.2	7.2	8.1	12.3

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total AEFI ^(a)	General AEFI ^(b)	Serious AEFI ^(c)			
					Subtotal	Death ^①	Anaphylaxis suspected ^②	Major AEFI ^③
Total	New	4,136,581	523	498	25	3	2	20
	Total		19,394	18,689	705	95	187	423
AstraZeneca	New	2,005,438	352	343	9	1	0	8
	Total		16,238	15,773	465	51	149	265
Pfizer	New	2,131,143	171	155	16	2	2	12
	Total		3,156	2,916	240	44	38	158

(a) Cases reported by healthcare institutions as suspected AEFI cases; does not indicate causal association

(b) Common symptoms following vaccination including redness, pain, swelling, muscle pain, fever, headache, chills, etc.

(c) Serious AEFI includes the following:

- ① Death,
- ② Anaphylaxis suspected (including anaphylactoid reactions)
- ③ Major AEFI: Adverse events of special interest (AESI), admission to ICU, critical condition, permanent disability/sequelae/etc.



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

8 May 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		701 (100)	126,745 (100)	244.46
Sex	Male	339 (48.36)	63,139 (49.82)	244.13
	Female	362 (51.64)	63,606 (50.18)	244.78
Age	80 or above	15 (2.14)	5,462 (4.31)	287.59
	70-79	34 (4.85)	9,083 (7.17)	251.81
	60-69	104 (14.84)	19,453 (15.35)	306.62
	50-59	125 (17.83)	23,461 (18.51)	270.69
	40-49	112 (15.98)	18,840 (14.86)	224.57
	30-39	111 (15.83)	17,158 (13.54)	243.54
	20-29	113 (16.12)	18,860 (14.88)	277.09
	10-19	58 (8.27)	8,907 (7.03)	180.29
0-9	29 (4.14)	5,521 (4.36)	133.08	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		5 (100)	1,865 (100)	1.47	165 (100)
Sex	Male	3 (60.00)	928 (49.76)	1.47	93 (56.36)
	Female	2 (40.00)	937 (50.24)	1.47	72 (43.64)
Age	80 or above	4 (80.00)	1,030 (55.23)	18.86	43 (26.06)
	70-79	0 (0.00)	530 (28.42)	5.84	65 (39.39)
	60-69	1 (20.00)	219 (11.74)	1.13	30 (18.18)
	50-59	0 (0.00)	62 (3.32)	0.26	17 (10.30)
	40-49	0 (0.00)	14 (0.75)	0.07	7 (4.24)
	30-39	0 (0.00)	7 (0.38)	0.04	3 (1.82)
	20-29	0 (0.00)	3 (0.16)	0.02	0 (0.63)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.	5.1	5.2.	5.3.	5.4.	5.5.	5.6.	5.7.	5.8.
Total	136	132	156	160	157	164	174	170	164	162	173	172	162	165

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)